European Journal of Endocrinology (EUR J ENDOCRINOL)

Publisher: European Federation of Endocrine Societies, BioScientifica

Journal description

The journal publishes original research papers, reviews, short communications and case reports within clinical and experimental endocrinology.

Current impact factor: 4.07

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 4.069
2013 Impact Factor 3.686
2012 Impact Factor 3.136
2011 Impact Factor 3.423
2010 Impact Factor 3.482
2009 Impact Factor 3.539
2008 Impact Factor 3.791
2007 Impact Factor 3.239
2006 Impact Factor 3.145
2005 Impact Factor 2.962
2004 Impact Factor 3.14
2003 Impact Factor 2.941
2002 Impact Factor 2.56
2001 Impact Factor 2.133
2000 Impact Factor 2.315
1999 Impact Factor 2.421
1998 Impact Factor 2.101
1997 Impact Factor 1.968
1996 Impact Factor 1.695
1995 Impact Factor 1.234

Impact factor over time

Impact factor

Additional details

5-year impact 3.94
Cited half-life 6.60
Immediacy index 0.73
Eigenfactor 0.02
Article influence 1.19
Website European Journal of Endocrinology website
Other titles European journal of endocrinology
ISSN 0804-4643
OCLC 29970781
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details


  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 12 months embargo
  • Conditions
    • In any repository
    • Publisher's version/PDF cannot be used
    • Set statement to accompany deposit (see policy)
    • Publisher last contacted on 18/04/2013
  • Classification
    ​ white

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Gestational diabetes (GDM) is defined as a glucose intolerance resulting in hyperglycaemia of variable severity with onset during pregnancy. This review aims to revisit the pathogenesis and aetiology of GDM in order to better understand its clinical presentation and outcomes. During normal pregnancy, insulin sensitivity declines with advancing gestation. These modifications are due to placental factors, progesterone, and estrogen. In a physiological situation, a compensatory increase in insulin secretion maintains a normal glucose homeostasis. GDM occurs if pancreatic beta-cells are unable to face the increased insulin demand during pregnancy. GDM is most commonly a forerunner of type 2 diabetes (T2D) - the most prevalent form of diabetes. These women share similar characteristics with predisposed subjects to T2D: insulin resistance before and after pregnancy, and carry more T2D risk alleles. Auto-immune and monogenic diabetes are more rare aetiologies of GDM. Adverse pregnancy outcomes of GDM are mainly related to macrosomia caused by foetal hyperinsulinism in response to high glucose levels coming from maternal hyperglycaemia. Screening recommendations and diagnosis criteria of GDM have been recently updated. High risk patients should be screened as early as possible using fasting plasma glucose, and if normal, at 24-28 weeks of gestation using 75g Oral Glucose Tolerance Test (OGTT). The treatment of GDM is based on education with trained nurses and dieticians, and if necessary insulin therapy.
    European Journal of Endocrinology 10/2015; DOI:10.1530/EJE-15-0378
  • European Journal of Endocrinology 09/2015; DOI:10.1530/EJE-15-0562
  • [Show abstract] [Hide abstract]
    ABSTRACT: Overt hypothyroidism in pregnant women is associated with a lower intelligence quotient in their children. More recently, subtle decreases in maternal thyroid function have also been associated with neurodevelopmental impairment in offspring. We tested the effect of hypothyroxinaemia during early pregnancy on school performance. This was a longitudinal study that included the data of 1,196 mother-child pairs from the Amsterdam Born Children and their Development study. Maternal serum free T4 and TSH were obtained at a median gestational age of 12.9 (interquartile range: 11.9-14.3) weeks. School performance was assessed at age 5 years and based on scores obtained in arithmetics and language tests from the national monitoring and evaluation system. Poor school performance was defined as a test result <25th percentile and subnormal school performance as a result <50th percentile of the norm population. To estimate the impact of possible non-response bias, we conducted inverse-probability weighted analyses. Maternal hypothyroxinaemia (i.e., a maternal free T4 in the lowest 10% of distribution) was associated with a 1.61 (95% confidence interval (CI): 1.05-2.47) -fold increased odds of subnormal arithmetic performance after adjustment for confounders (p= 0.03). However, the odds ratio dropped to 1.48 (95% CI: 0.94-2.32) after inverse-probability weighting (p= 0.09). No such relations were found with TSH. Maternal hypothyroxinemia at the end of the first trimester was associated with reduced performance in an arithmetics test, but not in a language test, in 5-year-old offspring. However, our results should be interpreted carefully, because of possible non-response bias.
    European Journal of Endocrinology 08/2015; DOI:10.1530/EJE-15-0397
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context: Previously we demonstrated that IGF1 receptor stimulating activity (IGF1RSA) offers advantages in diagnostic evaluation of adult GH deficiency (GHD). It is unknown whether IGF1RSA can be used to monitor GH therapy. Objective: To investigate the value of circulating IGF1RSA for monitoring GH therapy. Design/methods: 106 patients (54 m; 52 f) diagnosed with GHD were included; 22 were GH-naïve, 84 were already on GH treatment and discontinued therapy 4 weeks before baseline values were established. IGF1RSA was determined by the IGF1R kinase receptor activating assay, total IGF1 by immunoassay (Immulite). GH doses were titrated to achieve total IGF1 levels within the normal range. Results: After 12 months, total IGF1 and IGF1RSA increased significantly (total IGF1 from 8.1 (95% CI 7.3-8.9) to 14.9 (95% CI 13.5-16.4) nmol/l and IGF1RSA from 115 (95% CI 104-127) to 181 (95% CI 162-202) pmol/l). After 12 months, total IGF1 normalized in 81% of patients, IGF1RSA in 51% and remained below normal in more than 40% of patients in whom total IGF1 had normalized. Conclusions: During 12 months of GH treatment, changes in IGF1RSA did not parallel changes in total IGF1. Despite normalization of total IGF1, IGF1RSA remained subnormal in a considerable proportion of patients. At present our results have no short-term consequences for GH therapy of GHD patients. However, based on our findings we propose future studies to examine whether titrating GH dose against IGF1RSA results in a better clinical outcome than titrating against total IGF1.
    European Journal of Endocrinology 05/2015; 173(2). DOI:10.1530/EJE-15-0048
  • [Show abstract] [Hide abstract]
    ABSTRACT: Reduced circulating omentin levels have been reported in obesity and type 2 diabetes, but data were mostly derived from univariate analyses in small study samples. This study aimed to investigate the relationship between omentin, abnormal glucose tolerance and related metabolic factors in a large population-based cross-sectional study. Serum omentin was measured by ELISA in 1092 participants of the German KORA F4 survey (2006-2008). Associations between omentin serum levels, glucose tolerance (assessed with an oral glucose tolerance test) and diabetes-related factors were estimated using logistic and linear regression models respectively. Serum levels of omentin were not related to categories of glucose tolerance. However, serum omentin was positively associated with whole-body insulin sensitivity index (ISI (composite)) and HDL cholesterol and showed inverse associations with 2-h post-load glucose, fasting insulin, homeostasis model assessment-estimated insulin resistance, BMI and triglycerides (all P≤0.03 after adjustment for age, sex and lifestyle factors). Further adjustment for BMI and/or serum lipids attenuated the associations with parameters of glucose metabolism, whereas adjustment for serum adiponectin virtually abolished all aforementioned associations. In contrast, adjustment for omentin had no effect on the positive association between adiponectin levels and ISI (composite). The data from this large population-based cohort show that circulating omentin levels are associated with insulin sensitivity. Our observations further suggest that omentin acts via upregulation of adiponectin, which in turn affects lipid metabolism and thereby also indirectly enhances insulin sensitivity, but mechanistic studies are required to corroborate this hypothesis. © 2015 European Society of Endocrinology.
    European Journal of Endocrinology 04/2015; 172(4):423-32. DOI:10.1530/EJE-14-0879
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this systematic review and meta-analysis was to investigate whether mortality is increased in patients biochemically cured after initial treatment for Cushing's disease. This is a systematic review and meta-analysis of follow-up studies in patients cured from Cushing's disease after initial treatment was performed. Eight electronic databases were searched from 1975 to March 2014 to identify potentially relevant articles. Original articles reporting the standardized mortality ratio (SMR) for patients cured of Cushing's disease were eligible for inclusion. SMRs were pooled in a random effects model. I(2) statistics was used for quantification of heterogeneity. Eight cohort studies with a total of 766 patients were included. Out of eight studies, seven showed an SMR above 1.0 for cured patients. The pooled SMR was 2.5 (95% CI 1.4-4.2). The I(2) statistics showed evidence for statistical heterogeneity (78%, Q-statistics P<0.001), which was largely explained by two outliers. This meta-analysis reveals that mortality remains increased in patients with Cushing's disease even after initial biochemical cure remission, suggesting that cure does not directly reverse the metabolic consequences of long-term overexposure to cortisol. Other conditions such as hypopituitarism, including persistent adrenocortical insufficiency after surgery, may also contribute to the increased mortality risk. © 2015 European Society of Endocrinology.
    European Journal of Endocrinology 04/2015; 172(4):R143-R149. DOI:10.1530/EJE-14-0556
  • [Show abstract] [Hide abstract]
    ABSTRACT: Pituitary incidentalomas (PIs) are commonly encountered in clinical practice. The management of these asymptomatic pituitary lesions is still controversial. Systematic screening for subclinical or mild ACTH-dependent hypercortisolism (AH) is not presently recommended, due to the limited data available thus far on the epidemiological and clinical relevance of this condition in patients with PIs. As subclinical hypercortisolism (SH) was considered to be associated with chronic complications of overt cortisol excess, such as hypertension, diabetes, and osteoporosis, this disorder should be diagnosed at the early stage. The objective of this study was to evaluate the prevalence of hypercortisolism in a population of subjects with PIs. A total of 68 consecutive patients (48 females and 20 males, aged 18-82 years) without clinically overt hypercortisolism, who were referred for evaluation of PIs between January 2010 and March 2013, were prospectively investigated for AH. Pituitary hypercortisolism was diagnosed in the presence of cortisol >50 nmol/l after 1 mg dexamethasone suppression test, non-suppressed ACTH, and the additional finding of one of the following: urinary free cortisol (UFC) >193 nmol/24 h, and midnight serum and salivary cortisol levels >207 and 2.8 nmol/l respectively. Among patients with PIs, we found a 7.3% rate of pituitary hypercortisolism diagnosed with biochemical criteria and a 4.4% rate of histologically confirmed AH. Subclinical or mild hypercortisolism may be more common than generally perceived in patients with PIs. © 2015 European Society of Endocrinology.
    European Journal of Endocrinology 04/2015; 172(4):363-9. DOI:10.1530/EJE-14-0599
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To assess, in a pediatric population, the clinical characteristics and management of triiodothyronine-predominant Graves' disease (T3-P-GD), a rare condition well known in adults, but not previously described in children. Design We conducted a university hospital-based observational study. Methods All patients with GD followed for more than one year between 2003 and 2013 (n=60) were included. T3-P-GD (group I) was defined as high fT3 concentration (>8.0 pmol/l) associated with a normal fT4 concentration and undetectable TSH more than one month after the initiation of antithyroid drug (ATD) treatment. Group II contained patients with classical GD without T3-P-GD. Results Eight (13%) of the patients were found to have T3-P-GD, a median of 6.3 (3.0-10.5) months after initial diagnosis (n=4) or 2.8 (2.0-11.9) months after the first relapse after treatment discontinuation (n=4). At GD diagnosis, group I patients were more likely to be younger [6.8 (4.3-11.0) vs. 10.7 (7.2-13.7) years] and had more severe disease than group II patients, with higher serum TRAb levels: 40 (31-69) vs. 17 (8-25) IU/l, p<0.04 and with slightly higher serum fT4 [92 (64-99) vs. 63 (44-83) pmol/l] and fT3 [31 (30-46) vs. 25 (17-31) pmol/l] concentrations. During the three years following T3-P-GD diagnosis, a double dose of ATD was required and median serum fT4/fT3 ratio remained lower in group I than in group II. Conclusion Severe hyperthyroidism, with particularly high TRAb concentrations at diagnosis, may facilitate the identification of patients requiring regular serum fT3 determinations and potentially needing higher doses of ATD dosage during follow-up.
    European Journal of Endocrinology 03/2015; 172(6). DOI:10.1530/EJE-14-0959
  • [Show abstract] [Hide abstract]
    ABSTRACT: Posttraumatic pituitary hormone deficiency is often suggested. The impact of these predominantly mild and often irreproducible deficiencies on outcome is less clear. The study aim was to describe patient reported outcome in a national a-priori unselected cohort of patients with traumatic brain injury (TBI) in relation to deficiencies identified upon pituitary assessment. We conducted a nationwide population-based cohort study. Participants were Danish patients with a head trauma diagnosis recorded in the Danish Board of Health diagnostic code registry; 439 patients (and 124 healthy controls) underwent assessment of anterior pituitary function 2.5 years (median) after TBI. Questionnaires on health related quality of life (QoL)(SF36, EQ5D, QoLAGHDA) and fatigue (MFI-20) were completed in parallel to pituitary assessment. Patients with TBI had significant detriments in QoL. Impairment (mainly physical scales) related to pituitary deficiency, though only partially confirmed after adjustment for demographic differences. Hypogonadotrophic hypogonadism related to several QoL scores. Increasing impairments were observed with declining total-testosterone (men), but not free-testosterone or any other hormone concentrations. Total-testosterone was not independently related to impaired QoL and fatigue, after adjustment for demographics, and treatment with antidiabetics, opioids, antidepressants and anticonvulsants. Only a very limited relationship between pituitary hormone deficiencies and QoL/fatigue was demonstrated. Due to the dominating influence of concurrent comorbidities, pituitary deficiencies were not independently related to QoL/fatigue. Causality is still to be shown, and whether substitution therapy could be of additional relevance in selected patients needs to be proven.
    European Journal of Endocrinology 03/2015; 172(6). DOI:10.1530/EJE-14-1069
  • [Show abstract] [Hide abstract]
    ABSTRACT: Unilateral adrenalectomy is the first-line treatment for aldosterone-producing adenomas (APA). Hyperkalemia after adrenalectomy because of contralateral zona glomerulosa insufficiency has been reported. We investigated clinical risk factors to predict postoperative hyperkalemia in patients with APA undergoing adrenalectomy. The study was conducted by retrospective review of medical records from 2000-2012 at Seoul National University Hospital and two other tertiary centers. Data from 124 patients who underwent adrenalectomy were included. Hyperkalemia was defined as serum potassium >5.5 mmol/l. Clinical preoperative risk factors included age, blood pressure, plasma renin activity (PRA), plasma aldosterone concentration (PAC), serum potassium, serum creatinine, glomerular filtration rate (GFR), the mass size on pathology and mineralocorticoid receptor (MR) antagonist use. Thirteen of 124 patients (10.5%) developed postoperative hyperkalemia. The incidences of transient and persistent hyperkalemia were 3.2% and 7.3%, respectively. Preoperative PRA and PAC were not significantly different in postoperative hyperkalemic patients compared with normokalemic patients. Patients with persistent hyperkalemia were older, had a longer duration of hypertension, larger mass size on pathology, and lower GFR (all P <0.05). The incidence of postoperative hyperkalemia was not different between MR antagonist users and non-users. Older age (≥53 years), longer duration of hypertension (≥9.5 years), larger mass size on pathology (≥1.95 cm), and impaired preoperative renal function (GFR <58.2 ml/min) were associated with prolonged postoperative hyperkalemia in patients with APA. MR antagonist use did not prevent postoperative hyperkalemia. .
    European Journal of Endocrinology 03/2015; 172(6). DOI:10.1530/EJE-15-0074
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Cortisol excess due to adrenal adenomas or hyperplasia causes Cushing's syndrome. Recent genetic studies have identified a somatic PRKACA(L206R) mutation as a cause of cortisol-producing adenomas. We aimed to compare the clinical features of PRKACA-mutant lesions with those of CTNNB1 mutations, and to search for similar mutations in unilateral hyperplasia or tumors co-secreting aldosterone. Design, patients, and methods: In this study, 60 patients with cortisol excess who had adrenalectomies at our institution between 1992 and 2013 were assessed, and somatic mutations were determined by Sanger sequencing. A total of 36 patients had overt Cushing's syndrome, the remainder were subclinical: 59 cases were adenomas (three bilateral) and one was classified as hyperplasia. Four tumors had proven co-secretion of aldosterone. Results: Among cortisol-secreting unilateral lesions without evidence of co-secretion (n=52), we identified somatic mutations in PRKACA (L206R) in 23.1%, CTNNB1 (S45P, S45F) in 23.1%, GNAS (R201C) in 5.8%, and CTNNB1+GNAS (S45P, R201H) in 1.9%. PRKACA and GNAS mutations were mutually exclusive. Of the co-secreting tumors, two (50%) had mutations in KCNJ5 (G151R and L168R). The hyperplastic gland showed a PRKACA(L206R) mutation, while patients with bilateral adenomas did not have known somatic mutations. PRKACA-mutant lesions were associated with younger age, overt Cushing's syndrome, and higher cortisol levels vs non-PRKACA-mutant or CTNNB1-mutant lesions. CTNNB1 mutations were more significantly associated with right than left lesions. Conclusions: PRKACA(L206R) is present not only in adenomas, but also in unilateral hyperplasia and is associated with more severe autonomous cortisol secretion. Bilateral adenomas may be caused by yet-unknown germline mutations.
    European Journal of Endocrinology 03/2015; 172(6). DOI:10.1530/EJE-14-1113
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Although an inhibin B assay may be useful in the assessment of testicular function in a number of genital conditions, reliable reference ranges are still lacking. This study sought to establish the reference range for serum inhibin B by applying the updated Gen II assay. Design: This prospective study included 818 men referred for semen analysis: 377 were normozoospermic (reference group) and 441 presented at least one abnormal semen parameter (case group). Methods: Semen parameters were interpreted according to the 2010 WHO manual and David's modified classification for normal morphology. The inhibin B concentration was determined with the currently enzyme-linked immunosorbent assay. Results: In the reference group, the 2.5th percentile for inhibin B was 92 pg/mL and the 97.5th percentile for FSH was 7.8 IU/L. In the overall population, an inhibin B level <92 pg/ml was associated with increased odds ratio [95% Confidence Interval] for oligozoospermia (16.93 [9.82-29.18], p<0.0001), asthenozoospermia (4.87 [2.88-8.10], p<0.0001) and teratozoospermia (2.20 [1.31-3.68]. The combination of a FSH >7.8 IU/L and an inhibin B <92 pg/ml was associated with greater odds ratio for oligozoospermia (98.74 [23.99-406.35], p<0.0001) than for each hormone considered separately. Conclusion(s): A new reference range for serum inhibin B was established by the use of updated immunoassay. The correlations between hormone levels and semen parameters highlighted the importance of establishing these values with respect to the spermogram. When combined with FSH assay, the inhibin B range may be of value in the evaluation of spermatogenesis in a number of male genital conditions.
    European Journal of Endocrinology 03/2015; 172(6). DOI:10.1530/EJE-14-0932